List view / Grid view
The global generics drug market is anticipated to grow to $574.63 billion by 2030, owing to the increasing application of robotic process automation, branded medicine patent expiries and the rising prevalence of chronic diseases.
Sanofi invests $180 million equity in Owkin’s artificial intelligence (AI) and federated learning to advance oncology pipeline.
Opdivo and Yervoy displayed a 23 percent survival rate at three years compared to 15 percent with chemotherapy, Phase III trial shows.
Researchers have found that nintedanib shows promising effectiveness in halting the growth of human malignant pleural mesothelioma in preclinical models.
Combined treatment with two cancer immunotherapy drugs significantly prolonged survival in aggressive cancer malignant mesothelioma...
A study has provided strong evidence that certain carbon nanotubes used in manufacturing could pose the same cancer risk as asbestos...
14 April 2016 | By Victoria White, Digital Content Producer
Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and 59% response rate in malignant pleural mesothelioma...
29 February 2016 | By Victoria White
DETERMINE, the Phase IIb clinical trial of tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint of overall survival...
2 February 2016 | By Victoria White
Targovax has submitted a study protocol to the regulatory authorities in Spain to assess ONCOS-102 in patients with malignant pleural mesothelioma...
